The EAU regularly publishes press releases. Other news can be found in the News section or in the EAU News mailing. Stay up to date, and subscribe to the EAU Press Mailing List to receive the latest EAU press releases and other relevant information. Please subscribe here.
A major UK survey has shown that patients with urological cancer such as prostate, bladder or kidney cancer are five times more likely to commit suicide than people without cancer. The analysis also shows that cancer patients generally are around three times more likely to commit suicide than the general population and that the proportion of attempted suicides which result in a completed or successful suicide was higher in cancer patients, with a higher proportion still in patients with urological cancers.
A major international survey has found that around a quarter of patients are not receiving the recommended treatment for cancer of the penis. It also found that these patients had half the survival rate of those who were treated according to guidelines. The study, presented at the EAU conference in Copenhagen, finds that non-adherence is partly due to patients refusing treatment, or doctors being reluctant to treat appropriately or being unfamiliar with the best procedures.
Almost 4 in 10 men with high-risk or locally advanced prostate cancer (prostate cancer that is likely to or that has already spread beyond the prostate) may be “undertreated”* by the failure to use radiotherapy or in some circumstances surgery, according to results from the National Prostate Cancer Audit (NPCA). The most common form of under-treatment is the use of hormonal treatments alone without additional radiotherapy or surgery. This means that some of the men diagnosed with high-risk or locally advanced prostate cancer may not be receiving the best treatment, according to research presented at the European Association of Urology conference in London in March 2017.
People with learning difficulties are 4 times more likely to die of testicular cancer than the general population. This is the first work relating cancer deaths to learning difficulties, with researchers now testing if this finding applies to all cancers.
The need to pee at night (nocturia) – which affects most people over the age of 60 – is related to the amount of salt in your diet, according to new research presented at the European Society of Urology congress in London.
A new analysis raises concern over high prescription rates in the USA of a common drug used to treat overactive bladder. The drug, oxybutynin, when taken orally, is consistently linked with cognitive impairment and dementia in the elderly. The analysis shows that oxybutynin, is prescribed in more than a quarter of cases of overactive bladder (27.3%), even though other more suitable drugs are available. This work is presented at the European Association of Urology conference in London, where concerns are also being expressed about the lack of funded alternatives to oxybutynin in Europe.
A new study has found that reducing obstructive sleep apnea (where patients have difficulty in breathing while asleep -often associated with loud snoring) can reduce the need to get up and pee at night (nocturia). This study confirms the link between apnea and nocturia, and supports the idea that lifestyle management may contribute to reducing nocturia in certain cases. Nocturia affects more than half of men and women over the age of 50 ref1 and is reported as the most irritating of all voiding symptomsref2.
Screening for prostate cancer is controversial. It can save lives, but it can also lead to unnecessary diagnoses, followed by surgical or radiation procedures, which themselves may lead to severe side-effects. Now a new study, coming from the Dutch part of the European Randomised study for the Screening of Prostate Cancer (ERSPC) has found that MRI-based screening can reduce overdiagnosis by 50% and reduce unnecessary biopsies by 70%, potentially changing the equation for prostate cancer screening. This work, the first to confirm that the use of MRI in a population-based screening setting may be viable, is presented at the EAU conference in London.
New clinical trial results show that stem cells can restore sufficient erectile function to allow previously impotent men to have spontaneous intercourse. This is the first time stem cell therapy has produced patients who have recovered sufficient erectile function to enable intercourse. This is an early trial, which was primarily addressing safety and dosage (a Phase 1 trial), so the results need to be interpreted accordingly.
Scientists have piloted silicon biosensor chips which can rapidly identify the best antibiotics for treating bacterial infections. The system can direct clinicians to the best antibiotic treatment in around 2 to 6 hours, rather than upwards of 2 days which is typical of conventional tests. The new technology, which is still in development, is being presented at the European Association of Urology congress in London.